Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
06 Jul 2023
06 Jul 2023
Historique:
received:
14
03
2023
accepted:
21
06
2023
revised:
14
06
2023
medline:
6
7
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) is a malignancy still associated with poor survival rates, among others, due to frequent occurrence of therapy-resistant relapse after standard-of-care treatment with cytarabine (AraC). AraC triggers apoptotic cell death, a type of cell death to which AML cells often become resistant. Therefore, therapeutic options that trigger an alternate type of cell death are of particular interest. We previously identified that the glycan-binding protein Galectin-9 (Gal-9) has tumor-selective and non-apoptotic cytotoxicity towards various types of cancer, which depended on autophagy inhibition. Thus, Gal-9 could be of therapeutic interest for (AraC-resistant) AML. In the current study, treatment with Gal-9 was cytotoxic for AML cells, including for CD34
Identifiants
pubmed: 37407572
doi: 10.1038/s41420-023-01515-w
pii: 10.1038/s41420-023-01515-w
pmc: PMC10322858
doi:
Types de publication
Journal Article
Langues
eng
Pagination
228Subventions
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : KWF Kankerbestrijding (Dutch Cancer Society)
ID : KWF10709
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : No 813871
Informations de copyright
© 2023. The Author(s).
Références
Res Pharm Sci. 2021 Oct 15;16(6):612-622
pubmed: 34760009
Autophagy. 2017 May 4;13(5):955-966
pubmed: 28282266
BMC Cancer. 2017 Dec 14;17(1):852
pubmed: 29241450
Clin Immunol. 2008 Apr;127(1):78-88
pubmed: 18282810
Nat Immunol. 2005 Dec;6(12):1245-52
pubmed: 16286920
Blood. 2013 Oct 3;122(14):2467-76
pubmed: 23970379
Int J Mol Sci. 2021 Feb 26;22(5):
pubmed: 33652766
Exp Hematol. 2007 Oct;35(10):1538-49
pubmed: 17889721
Mol Med Rep. 2016 Apr;13(4):3433-40
pubmed: 26935591
Biochem Biophys Res Commun. 2010 Apr 2;394(2):317-22
pubmed: 20206131
Nat Commun. 2020 Aug 27;11(1):4286
pubmed: 32855403
Autophagy. 2014 Aug;10(8):1359-68
pubmed: 24991840
Int J Oncol. 2015;46(6):2419-30
pubmed: 25823465
BMC Cancer. 2020 Dec 4;20(1):1193
pubmed: 33276759
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188464
pubmed: 33157161
Res Pharm Sci. 2018 Dec;13(6):557-565
pubmed: 30607153
J Invest Dermatol. 2012 Sep;132(9):2302-5
pubmed: 22572821
Biomed Pharmacother. 2015 Jul;73:87-96
pubmed: 26211587
Oncol Rep. 2015 Oct;34(4):1761-70
pubmed: 26260906
Int J Oncol. 2011 Apr;38(4):911-9
pubmed: 21290089
Med Res Rev. 2013 Jun;33 Suppl 1:E102-26
pubmed: 21793015
J Cancer Res Clin Oncol. 2014 Jun;140(6):909-20
pubmed: 24659340
J Biol Chem. 2013 Nov 1;288(44):31761-71
pubmed: 24062304
Postgrad Med J. 1978 Feb;54(628):108-12
pubmed: 273209
Cell Death Dis. 2017 Jul 13;8(7):e2927
pubmed: 28703806
Cancer Drug Resist. 2022 Mar 14;5(1):233-244
pubmed: 35582535
Int J Mol Sci. 2017 Jan 01;18(1):
pubmed: 28045432
Mol Cancer Res. 2010 Jul;8(7):994-1001
pubmed: 20571063
Autophagy. 2015;11(8):1373-88
pubmed: 26086204
J Biol Chem. 2015 Jul 3;290(27):16797-811
pubmed: 25947381
Expert Opin Pharmacother. 2017 Nov;18(16):1765-1780
pubmed: 29017371
Clin Immunol. 2012 Apr;143(1):51-8
pubmed: 22341088
PLoS One. 2014 Apr 08;9(4):e94374
pubmed: 24714637
Blood. 2016 Jan 7;127(1):53-61
pubmed: 26660429
J Pers Med. 2021 Aug 10;11(8):
pubmed: 34442423
Autophagy. 2021 Jan;17(1):1-382
pubmed: 33634751
Cell Stem Cell. 2015 Sep 3;17(3):341-52
pubmed: 26279267
Med Res Rev. 2019 Mar;39(2):517-560
pubmed: 30302772
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
PLoS One. 2013 May 31;8(5):e65616
pubmed: 23741502
J Clin Oncol. 2011 Feb 10;29(5):475-86
pubmed: 21220609
Int J Mol Sci. 2019 Aug 19;20(16):
pubmed: 31430907
Clin Cancer Res. 2004 Jun 1;10(11):3737-44
pubmed: 15173080
Cancer Sci. 2013 Apr;104(4):502-7
pubmed: 23320492
Curr Oncol Rep. 2020 Feb 11;22(3):27
pubmed: 32048054
J Immunol. 2003 Apr 1;170(7):3631-6
pubmed: 12646627
Melanoma Res. 2016 Oct;26(5):429-41
pubmed: 27455380
FEBS Lett. 2005 Apr 11;579(10):2058-64
pubmed: 15811318
Clin Cancer Res. 2014 May 1;20(9):2400-9
pubmed: 24610825
Cancer Manag Res. 2018 Mar 02;10:403-416
pubmed: 29535553